Dr. Edward Nardell, associate professor, Harvard Medical School and Harvard School of Public Health, has been engaged in tuberculosis control since the mid-70s. He served at various times as TB Control Officer for the health departments of Boston, Cambridge, and Massachusetts, the latter for 18 years. In the early 80s he hired a young man about to start medical school, Paul Farmer, as a Creole-speaking TB outreach worker in Cambridge. Dr. Nardell now works in the Brigham & Women's Hospital Division of Global Health Equity under Dr. Farmer's leadership. His research focus for nearly 40 years has been TB transmission and control, reviving the classic human-to-guinea pig model of another mentor, Dr Richard Riley. Recent publications have documented transient TB infection in the guinea pig, the efficacy of new approaches to upper room germicidal UV air disinfection, and the rapid impact of treatment on TB transmission. An inquiry by students of Harvard Prof. David Edwards regarding our interest in nanoparticle formulations of inhaled TB drugs led to a phase I clinical trial of dry powder capreomycin. The hypothesis that an inhaled novel antibiotic might render even highly drug-resistant patients less infectious led to the first (known) clinical trial of an inhaled antibiotic, dry powder polymixin E (colistin), in TB patients. The potential use of inhaled antibiotics for TB and NTM treatment remains an ongoing research and clinical interest.